Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
SGMO
$9.41
Sangamo Therapeutics
($.04)
(.42%)
SGMO
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus: ($0.30)
Revenue: $19.27 Mil
Wednesday
Feb 5
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Wednesday, November 6, 2019
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
What do you expect when SGMO reports earnings?
Beat
Meet
Miss
Where is SGMO's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$9.68
$9.60
$9.51
$9.43
Support
$9.34
$9.26
$9.17
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.
Peers
Biogen
Gilead Sciences
Amgen
Bluebird Bio
Neurocrine Biosciences
Seattle Genetics
Qiagen N.V.
Repligen
BioCryst Pharmaceuticals
Novavax
Expectations
›
Sangamo Therapeutics
